Co-founder and CEO of pharmaceutical development company, Nuformix (NFX) , Dr. Daniel Gooding joined us to discuss the company's lead asset NXP001 beginning clinical trials and their growing role in China.
Tune in as Dr. Gooding lays out NFX's unique business model, repurposing approved drugs and innovative therapies for unmet medical needs.
For more news and updates on Nuformix:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
